portsf.blogg.se - Novavax information

Nuvaxovid is a protein-based COVID-19 vaccine (the first available in NZ), which can be used as a primary course with 2 doses, given at least 3 weeks apart, ideally 8 weeks apart. Comirnaty continues to be the preferred vaccine. Use as an additional booster is limited by the criteria for additional boosters. Nuvaxovid, the Novavax COVID-19 vaccine is a recombinant protein vaccine that has been approved to be used as a primary vaccination course from 12 years of age and as a first or additional booster dose for people aged 18 years and older in Aotearoa New Zealand. NOTE: changes came in 1 April 2023 - see here for details. IMAC quick take: International COVID-19 vaccine current events.Who can't have the Comirnaty (Pfizer/BioNTech) COVID-19 vaccine?.Third primary dose and booster information.Vaccine safety in pregnancy and other special groups.Adverse Events Following Immunisation: Reporting and Monitoring.Comirnaty (3mcg) 6 months - 4 years, maroon cap.

Management of anaphylaxis and administration of adrenaline course.

Tagata Pasifika workforce info and support.

Covid-19 Immunisation Register (CIR) administration course.

Pharmacy Technician COVID-19 vaccine storage and preparation course.

COVID-19 vaccination info hub for community groups and workplaces.

COVID-19 vaccinator – working under supervision course.

Other COVID-19 Vaccination Workforce Education.

The COVID-19 Authorised Vaccinator Education Course.

COVID-19 Education for Health Professionals.

Vaccinating Health Worker Stage 1 Training.

Vaccinator Health Worker - Supervisor Course.

Go to the Immunisation Advisory Centre's main website.

Our role: The NZ COVID-19 vaccination programme.